166TiP NCT03878849: A phase II trial of stenoparib/2X-121, a novel dual inhibitor of PARP and the WNT pathway, in platinum resistant/ineligible ovarian cancer patients
2X-121 is an inhibitor of PARP1/2 and Tankyrase, a key enzyme activating the WNT/Beta-catenin oncogenic pathway. In a prior phase II study enrolling only advanced, recurrent ovarian cancer patients (pts) (14 platinum resistant, 1 primary platinum refractory) with a 2X-121-specific Drug Response Predictor (DRP) score of 50+, 2X-121 dosed BID (600mg total daily dose) showed evidence for durable clinical benefit. Benefit was evident in pts previously treated with PARP inhibitors and regardless of BRCA status.
Authors
- P. Gimsing
- R.M. Glasspool
- J.L. Iglesias
- J.R. Graff
- F. Musa
- S.M. Knudsen
- T. Jensen
- A. Nielsen
- M. Madsen
- M. Gargano
- K.N. Moore
- M. Jacobsen
- R. Kristeleit
- J. Bohn
Institutions
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Canadian Association of Gastroenterology (CA)
- Beatson West of Scotland Cancer Centre (GB)
- Swedish Medical Center (US)
- Io Therapeutics (United States) (US)
- MC2 Therapeutics (Denmark) (DK)
- University of Oklahoma Health Sciences Center (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108213
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00